Table 1.
Baseline characteristics of patients in the CAD vs NCAD groups, and the stenosis vs non-stenosis subgroups
| CAD | NCAD (12) | |||
|---|---|---|---|---|
| Stenosis (15) | Non-Stenosis (13) | Total (28) | ||
| Clinical characteristics | ||||
| Age (years) | 61.73 ± 4.28 | 60.08 ± 3.80 | 60.96 ± 4.08 | 58.50 ± 5.27 |
| Male (%) | 8 (53.3) | 10 (76.9) | 18 (64.3) | 5 (47.1) |
| BMI (kg/m2) | 25.48 ± 3.91 | 25.93 ± 2.82 | 25.69 ± 3.39 | 23.09 ± 2.32*§ |
| Waist circumference (cm) | 90.11 ± 9.68 | 94.15 ± 13.31 | 91.99 ± 11.47 | 81.05 ± 8.94*§ |
| Hypertension (%) | 4 (26.7) | 3 (23.1) | 7 (25.0) | 1 (8.3) |
| T2DM (%) | 8 (53.3) | 8 (61.5) | 16 (57.1) | 3 (25.0) |
| Smoking (%) | 9 (60.0) | 9 (69.2) | 18 (64.3) | 4 (33.3) |
| LVEF (%) | 57.73 ± 10.31 | 55.92 ± 9.51 | 56.89 ± 9.80 | 56.58 ± 7.50 |
| Laboratory examinations | ||||
| Fasting glucose (mmol/L) | 5.35 (4.98, 7.30) | 5.37 (5.02, 5.65) | 5.36 (5.00, 6.30) | 5.28 (4.77, 6.04) |
| Glycosylated serum protein (%) | 15.00 (14.20, 16.80) | 14.50 (13.80, 17.20) | 14.65 (13.88, 17.03) | 14.55 (14.05, 17.75) |
| Fasting insulin(μU/ml) | 73.10 (13.40, 104.50) | 9.80 (6.05, 47.70) | 16.35 (7.98, 80.88) | 22.30 (11.03, 26.20) |
| HOMA-IR | 2.49 (1.57, 6.71) | 17.38 (3.82, 27.92) | 4.28 (2.07, 25.75) | 4.27 (2.40, 8.09)§ |
| Triglycerides (mmol/L) | 1.32 (0.91, 2.04) | 1.71 (1.15, 2.50) | 1.52 (1.02, 2.22) | 1.46 (1.07, 2.59) |
| Total cholesterol (mmol/L) | 4.25 ± 1.27 | 4.36 ± 0.88 | 4.30 ± 1.09 | 4.87 ± 1.32 |
| HDL-C (mmol/L) | 0.96 (0.82, 1.18) | 0.81 (0.73, 1.06) | 0.88 (0.77, 1.17) | 1.18 (0.89, 1.73) |
| LDL-C (mmol/L) | 2.74 ± 1.31 | 2.67 ± 0.93 | 2.70 ± 1.13 | 3.34 ± 0.84 |
| Serum creatinine (μmol/L) | 74.60 (65.50, 83.10) | 82.10 (76.15, 93.95)# | 78.70 (66.98, 86.60) | 79.90 (65.03, 84.13) |
| Homocysteine (μmol/L) | 15.50 (11.00, 21.90) | 14.20 (11.40, 22.90) | 14.35 (11.05, 21.90) | 14.45 (10.93, 20.08) |
| hsCRP (mg/L) | 1.02 (0.38, 3.85) | 1.01 (0.74, 2.28) | 1.02 (0.57, 3.00) | 2.35 (0.67, 5.09) |
| BNP (pg/ml) | 89.00 (43.00, 164.00) | 85.00 (30.50, 169.50) | 87.00 (43.00, 157.75) | 165.5 (87.75, 252.25) |
| cTnI (μg/L) | 0.01 (0, 0.02) | 0.01 (0, 0.015) | 0.01 (0, 0.02) | – |
| Medications | ||||
| Aspirin (%) | 6 (40.0) | 8 (61.5) | 14 (50.0) | 0 (0)*§ |
| Nitrates (%) | 13 (86.7) | 13 (100) | 26 (92.9) | 2 (16.7)*§ |
| ACEI/ARB (%) | 2 (13.3) | 2 (15.4) | 4 (14.3) | 1 (8.3) |
| Statins (%) | 9 (60.0) | 6 (46.2) | 15 (53.6) | 0 (0)*§ |
| β-blockers (%) | 9 (60.0) | 11 (84.6) | 20 (71.4) | 0 (0)*§ |
| Calcium channel blockers (%) | 3 (20.0) | 4 (30.8) | 7 (25.0) | 0 (0) |
| Insulin (%) | 2 (13.3) | 2 (15.4) | 4 (14.3) | 1 (8.3) |
| Oral hypoglycemic agents (%) | 3 (20.0) | 2 (15.4) | 5 (17.9) | 1 (8.3) |
Data are shown as mean ± SD, median (lower quartile, upper quartile), or number (%)
CAD coronary artery disease, NCAD non-coronary artery disease, BMI body mass index, LVEF left ventricular ejection fraction, HOMA-IR homeostasis model assessment of insulin resistance, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, BNP brain natriuretic peptide, cTnI cardiac troponin I, T2DM type 2 diabetes, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker
* P < 0.05, CAD group vs NCAD group
§ P < 0.05, non-stenosis subgroup vs NCAD group
# P < 0.05, stenosis subgroup vs non-stenosis subgroup